B of A Securities Rates Taysha Gene Therapies (TSHA) buy

Analyst Tazeen Ahmad at B of A Securities keeps a buy rating on Taysha Gene Therapies, aligning with a broader group of bullish Wall Street firms tracking the biotech company, a 61.03% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 9:01 AM EDT · Updated Jun 26, 2026, 7:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B of A Securities rated Taysha Gene Therapies, Inc. ($TSHA) "buy" with a $10 price target on June 23, 2026.

Since the rating, $TSHA is down 0.7% after 1 week, down 15.0% after 1 month and down 47.2% to date (from the $6.86 close on Jun 23, 2026).

TSHA Taysha Gene Therapies, Inc.

$3.62 -31.05% year to date

Daily close · Oct 16, 2026

Key Points

B of A Securities analyst Tazeen Ahmad reaffirmed a buy rating on Taysha Gene Therapies, Inc. (NasdaqGS: TSHA) with a $10.00 price target on June 23, 2026.
B of A Securities's $10 price target implies 61.03% upside from Taysha Gene Therapies, Inc.'s ($TSHA) current $6.21 share price.
The broader analyst community holds a strong buy consensus across 13 opinions, backed by a mean target price of $13.00.
Shares of Taysha Gene Therapies recently traded at $6.21, moving within a 52-week range of $2.87 to $7.30.

Get $TSHA trade alerts by text

We text you when insiders, Congress or big funds trade $TSHA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Taysha Gene Therapies, Inc. alert may contain errors. Disclosures

B of A Securities Maintains Buy Call on Taysha Gene Therapies

On June 23, 2026, analyst Tazeen Ahmad at B of A Securities reaffirmed a buy rating on Taysha Gene Therapies, Inc. (NasdaqGS: TSHA), keeping the price target at $10.00. This update is part of a series of reviews from major financial institutions assessing the clinical-stage biotech firm's pipeline of gene therapies targeting central nervous system disorders.

Analyst rating track record

B of A Securities vs. the S&P 500

YTD return +3.70% hypothetical

All-time return +26.99% S&P 500 +26.21%

vs. S&P 500 +0.78% ahead of the index

Hypothetical returns from B of A Securities's disclosed trades, not real profit or advice. How we model this.

Wall Street Analyst Coverage and Price Targets

B of A's view sits alongside a wave of recent notes from other research firms covering the stock. On September 17, 2026, Wolfe Research initiated coverage with an Outperform rating. Earlier, on July 21, 2026, Goldman Sachs maintained a buy rating while lifting its target to $13.00 from $11.00. Citizens also kept a market outperform rating on July 2, 2026, with an 11.00 target. Needham maintained a buy rating and a $12.00 target on June 30, 2026. Baird kept an outperform rating on June 30, 2026, raising its target to $15.00 from $12.00. BMO Capital maintained an outperform rating on June 23, 2026, moving its target to $14.00 from $10.00, while Citizens maintained a market outperform rating on the same day with an 11.00 target, up from $8.00. Across the wider analyst community, the stock carries a strong buy recommendation from 13 analysts, with a mean price target of $13.00, a high target of $19.00, and a low target of $9.00.

Taysha Stock Performance and Market Context

Shares recently changed hands at $6.21, giving the Dallas-based biotechnology company a market capitalization of roughly $1.64 billion. The stock trades above its 50-day moving average of $5.78 and its 200-day moving average of $5.48. Taysha shares move within a 52-week range spanning from a low of $2.87 to a high of $7.30, with a beta of 1.17 indicating moderate sensitivity to market swings.

12-month forecast

$TSHA price target

Taysha Gene Therapies, Inc. daily closes and this analyst's $10 target. Not advice.

What Taysha Gene Therapies Does

Taysha Gene Therapies is a clinical-stage biotechnology company centered on developing and commercializing adeno-associated virus-based gene therapies. Its pipeline addresses severe monogenic central nervous system diseases, including programs for Rett syndrome, giant axonal neuropathy, and angelman syndrome, through research agreements with academic institutions like The University of Texas Southwestern Medical Center.

Looking Ahead for Taysha

The company is scheduled to release its next set of quarterly financial results on November 4, 2026, which will provide further details on its clinical progress and financial standing. Investors will likely look to upcoming data readouts and regulatory updates as the primary catalysts driving analyst sentiment forward.